Shares of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) have received an average rating of “Hold” from the seven brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $5.67.

A number of research analysts have recently commented on ADMP shares. Zacks Investment Research downgraded Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday. ValuEngine downgraded Adamis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, September 4th. B. Riley upgraded Adamis Pharmaceuticals from a “sell” rating to a “neutral” rating in a research report on Tuesday, July 23rd. Dawson James started coverage on Adamis Pharmaceuticals in a research report on Tuesday, July 2nd. They set a “buy” rating for the company. Finally, Maxim Group set a $6.00 target price on Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 9th.

A number of large investors have recently added to or reduced their stakes in ADMP. Wedbush Securities Inc. raised its holdings in Adamis Pharmaceuticals by 139.8% during the 2nd quarter. Wedbush Securities Inc. now owns 44,600 shares of the specialty pharmaceutical company’s stock valued at $58,000 after buying an additional 26,000 shares during the period. A.R.T. Advisors LLC raised its holdings in Adamis Pharmaceuticals by 143.8% during the 2nd quarter. A.R.T. Advisors LLC now owns 61,711 shares of the specialty pharmaceutical company’s stock valued at $80,000 after buying an additional 36,400 shares during the period. GSA Capital Partners LLP purchased a new stake in Adamis Pharmaceuticals during the 2nd quarter valued at $181,000. Morgan Stanley raised its holdings in Adamis Pharmaceuticals by 189.7% during the 2nd quarter. Morgan Stanley now owns 757,124 shares of the specialty pharmaceutical company’s stock valued at $984,000 after buying an additional 495,793 shares during the period. Finally, BlackRock Inc. raised its holdings in Adamis Pharmaceuticals by 1.5% during the 2nd quarter. BlackRock Inc. now owns 962,687 shares of the specialty pharmaceutical company’s stock valued at $1,252,000 after buying an additional 14,312 shares during the period. Institutional investors own 12.09% of the company’s stock.

Shares of NASDAQ ADMP remained flat at $$0.54 during midday trading on Thursday. The stock had a trading volume of 1,864,356 shares, compared to its average volume of 829,943. The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.79 and a current ratio of 1.04. Adamis Pharmaceuticals has a 52-week low of $0.49 and a 52-week high of $3.29. The stock has a 50 day moving average of $0.79 and a 200 day moving average of $1.36.

Adamis Pharmaceuticals (NASDAQ:ADMP) last posted its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). The firm had revenue of $5.77 million for the quarter, compared to the consensus estimate of $5.82 million. Adamis Pharmaceuticals had a negative net margin of 205.32% and a negative return on equity of 86.04%. As a group, equities analysts predict that Adamis Pharmaceuticals will post -0.46 EPS for the current fiscal year.

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.

Recommended Story: Consumer behavior in bull markets

Analyst Recommendations for Adamis Pharmaceuticals (NASDAQ:ADMP)

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.